Effect of sorafenib on des-γ-carboxyprothrombin secretion by a human hepatocellular carcinoma cell line

Patients with hepatocellular carcinoma (HCC) who respond to sorafenib have been reported to exhibit an increase in the level of des-γ-carboxyprothrombin (DCP) in the blood, subsequent to the initiation of sorafenib treatment. In the present study, the levels of secretion of DCP and DCP with more γ-c...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogasawara, Sachiko, Nakayama, Masamichi, Akiba, Jun, Kusano, Hironori, Yano, Hirohisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530138/
https://www.ncbi.nlm.nih.gov/pubmed/28781657
http://dx.doi.org/10.3892/ol.2017.6451

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530138/
https://www.ncbi.nlm.nih.gov/pubmed/28781657
http://dx.doi.org/10.3892/ol.2017.6451

Ejemplares similares